Indian journal of cancer最新文献

{"title":"Cetuximab in platinum-ineligible patients with locally advanced squamous cell carcinoma of the head and neck: Consensus from India.","authors":"Agarwala Vivek, Aggarwal Shyam, Agrawal Shyam, M V Chandrakanth, Choudhary Vaibhav, S Dattatreya Palanki, Gore Adwaita, Kapoor Akhil, Kumar Prabhash, M Lokeshwar Nilesh, M Vamshi Krishna, K Vaid Ashok, N P Mohapatra, B Parekh Bhavesh, Patel Kaushal, Saha Rajat, Singh Ashish, Singh Randeep, Talreja Vikas, S Udupa Karthik, Gajanan Panchal, Maneesha Khalse, Gurunath Chavan","doi":"10.4103/ijc.ijc_862_24","DOIUrl":"10.4103/ijc.ijc_862_24","url":null,"abstract":"<p><strong>Abstract: </strong>Locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN) are one of the most common cancers globally and in India. Though many treatment options are available for LA-SCHHN, chemotherapy administered concurrently with radiotherapy (CCRT) is the most common treatment modality. Cisplatin-based CCRT is the guideline-recommended standard of care (SoC) in definitive and adjuvant settings. However, cisplatin-based CCRT often fails or cannot be administered due to toxicity. Hence, 60% of LA-SCCHN patients experience locoregional recurrence, and 20% experience distant metastasis. Many of these patients are cisplatin-ineligible/unfit due to absolute or relative contraindications; thus, continued cisplatin-based CCRT is unsuitable for them. Hence, alternative treatment strategies have been suggested for cisplatin-unfit LA-SCCHN patients and include docetaxel, carboplatin, and cetuximab-based regimens. Of these, docetaxel and carboplatin-based regimens have an unfavorable toxicity profile when compared with cetuximab-based regimens. Additionally, cetuximab-based regimens have demonstrated good locoregional control (LRC), improved disease-free survival (DFS), and OS (including 5-year OS) in LA-SCCHN patients. Therefore, Indian and international guidelines recommend cetuximab-based regimens for cisplatin-ineligible/unfit LA-SCCHN patients, Cetuximab is a costly drug for Indian patients. However, with the availability of cetuximab biosimilars, it has become possible to extend the drug's benefits to cisplatin-ineligible/unfit LA-SCCHN patients in India. Hence, this Expert opinion from India was organized, and nine consensus statements were drafted to highlight the various clinical settings where cetuximab-based regimens can benefit cisplatin-ineligible/unfit LA-SCCHN patients. An attempt was also made to understand the burden and causes of cisplatin ineligibility and toxicity in Indian patients.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"480-492"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial papillary thyroid cancer; A male case with breast and thyroid cancer and his three sisters with thyroid cancer: A case series and review of the literature.","authors":"Sevde N Fırat, Abdullah Durhan","doi":"10.4103/ijc.ijc_520_22","DOIUrl":"10.4103/ijc.ijc_520_22","url":null,"abstract":"<p><strong>Abstract: </strong>Thyroid cancer is the most widespread endocrine malignancy. Of all the cases of thyroid cancer, approximately 95% arise from follicular cells. Familial non-medullary thyroid cancers constitute 3-9% of all the reported cases of thyroid cancer and are diagnosed by the presence of two or more first-degree relatives with cancer. Most familial cases of non-medullary thyroid cancer are caused by papillary thyroid cancer and its histological variants. Although some genes predisposing to familial papillary thyroid cancer have been identified, their functionality is unclear, and routine examination is not recommended. Some of these cases may be syndromic, but most cases (>95%) are non-syndromic. Various researchers have suggested an association between familial papillary thyroid cancers and earlier age of onset, higher multifocal tumor rate, extrathyroid enlargement, lymph node metastasis, and disease recurrence. Therefore, screening and close follow-up of other family members are essential when familial papillary cancer is diagnosed. This case report presents a familial papillary thyroid cancer series involving an index male patient with a breast cancer history and his three sisters with thyroid papillary cancer.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"552-556"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleomorphic undifferentiated sarcoma arising in a burn scar: Report of a case and review of literature.","authors":"Ranganath Ratnagiri, Shantveer G Uppin","doi":"10.4103/ijc.ijc_511_22","DOIUrl":"10.4103/ijc.ijc_511_22","url":null,"abstract":"<p><strong>Abstract: </strong>The skin is the largest organ in the human body, and skin cancers are some of the most common malignancies seen across the world. About 80% of all skin cancers are basal cell carcinomas (BCC), 16% are squamous cell cancers (SCC), and 4% are melanomas. In contrast, the most common cancers that arise in a burn scar are squamous cell cancers. The burned area is at risk of constant and chronic irritation due to activities of daily living because the covering lacks hydration and elasticity, as compared to normal skin. Malignant transformation of these areas is accelerated by the prolonged duration of the ulcer, injury, constant irritation, infection, and poor hygiene. There have been anecdotal reports of sarcomas arising in a burn scar, with a total of 21 cases being reported so far in the literature. We present the clinical and pathological details of a 50-year-old lady with a pleomorphic undifferentiated sarcoma arising from a neglected burn scar, who needed palliative surgery to relieve her pain. This case report focuses attention on an unusual presentation of an aggressive tumor in the background of a neglected burn scar and emphasizes the need for early and appropriate management of all non-fatal burn patients.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"557-559"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenocortical carcinoma presenting with extensive striae: A case report and literature review.","authors":"Ayse Ozden, Zerrin Orbak, Ebru Sener, Gozde Doymus, Hakan Doneray","doi":"10.4103/ijc.ijc_87_24","DOIUrl":"10.4103/ijc.ijc_87_24","url":null,"abstract":"<p><strong>Abstract: </strong>Adrenocortical tumors are rare tumors in childhood. Virilization is the most common symptom, but about 5.5% of patients may also present with isolated Cushing's syndrome. A girl 15 years and 8 months of age presented with complaints of striae on her legs, acne for 2 weeks, and amenorrhea for 2 months. On physical examination, extensive striae were observed on her legs and abdomen. On hormonal investigation, her adrenocorticotropic hormone level was <5 pg/ml, cortisol was 35.4 µg/dl. Her hypercortisolism raised suspicion of Cushing's syndrome. Adrenal MRI revealed a right adrenal mass approximately 9 cm in diameter. Pleural metastasis was detected and the patient was diagnosed as having stage 4 adrenocortical carcinoma. Despite treatment, she died 9 months after diagnosis. Our case followed an aggressive clinical course and was unique due to the presence of extensive striae without pronounced virilization or Cushingoid symptoms.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"548-551"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine's role in enhancing lung cancer treatment: Exploring mechanisms, efficacy, and adjuvant potential.","authors":"Manju Bargavi Sakthivel, Prabhavathy Devi Narayanan Doss, Malchi Suresh, Tharani Munusamy, Nalini Devarajan, Naresh Kumar Kodaganti","doi":"10.4103/ijc.ijc_846_24","DOIUrl":"10.4103/ijc.ijc_846_24","url":null,"abstract":"<p><strong>Abstract: </strong>Berberine (BBR), a bioactive compound from various plants, shows significant therapeutic promise against lung cancer. Research indicates that berberine effectively inhibits cell proliferation in lung cancer cell lines and promotes apoptosis. Its mechanisms of action include inducing apoptosis and inhibiting metastasis-related pathways, showcasing its multifaceted approach to tumor suppression. Berberine also influences important signaling pathways like mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, and nuclear factor kappa-light-chain-enhancer of activated B cells, thereby boosting its anti-cancer properties. Preclinical animal studies have further demonstrated berberine's effectiveness, especially when combined with conventional chemotherapy, suggesting a synergistic relationship that could enhance treatment efficacy. These promising results have led to ongoing clinical trials exploring berberine's potential as part of lung cancer treatment regimens. However, challenges persist regarding dosage standardization, bioavailability, and the translation of preclinical results into clinical applications. This review highlights the therapeutic mechanisms of berberine, its potential efficacy as a standalone or adjunctive treatment, and the obstacles that must be addressed to leverage its benefits in lung cancer therapy fully. Overcoming these challenges may provide valuable opportunities for improving treatment outcomes, positioning berberine as a key component in future lung cancer therapies. Continued research is essential to better understand its precise mechanisms and enhance its clinical application.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"471-479"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and safety study of CDK4/6 inhibitors in hormone-positive metastatic breast cancer - A real-world tertiary cancer center experience.","authors":"K S Sandeep, Sandhya Appachu, Ravi B Diwaker, Sai Vivek, Vijai V S Simha","doi":"10.4103/ijc.ijc_643_23","DOIUrl":"10.4103/ijc.ijc_643_23","url":null,"abstract":"<p><strong>Background: </strong>CDK4/6 inhibitors have become the standard of care for the treatment of HR+ metastatic breast cancer (MBC) based on clinical trials. However, real-world experience and efficacy in various subgroups are still lacking. Therefore, we conducted a study to analyze the use of CDK4/6 inhibitors in the treatment of HR-positive MBC and assess the related outcomes.</p><p><strong>Methods: </strong>A total of 120 patients who received CDK4/6 inhibitors from 2015 to 2021 were analyzed. Detailed clinical, demographic information and tumor-related factors were obtained for each patient. Progression-free survival (PFS), toxicity profile, and tolerance to CDK4/6i were analyzed and correlated.</p><p><strong>Results: </strong>Among the 120 patients analyzed, 100 received palbociclib, while ribociclib, and abemaciclib were given to ten patients each. The median age of the population was 57 years. With a median follow-up of 28 months, the median PFS and overall survival (OS) were 25 and 54 months, respectively. The PFS did not significantly differ among different anti-hormonal agents used in combination with CDK4/6 inhibitors. Patients who were resistant to endocrine therapy had a shorter PFS compared to treatment-naive MBC patients (22 versus 40 months). Patients with strong hormonal receptor expression had a significantly better PFS compared to those with weak expression (25 versus 14 months). Her2Neu-negative patients responded better than those with low positive expression (P = 0.039). Visceral metastatic disease was associated with a significantly shorter PFS (17 months) compared to skeletal metastasis (32 months). There was no statistical significance when CDK4/6 inhibitors were used in different lines of treatment or with dose reduction.</p><p><strong>Conclusion: </strong>CDK4/6 inhibitors demonstrate similar responses and better tolerance in real-world evidence. Further studies are necessary to identify other predictive and resistance factors for the use of CDK4/6 inhibitors.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"541-547"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of interstitial brachytherapy in extremity sarcoma-treatment outcomes and current concepts.","authors":"Amar Kamat, Anto Gopurathingal, Pramod S Chinder, Suraj Hindiskere, M S Belliappa","doi":"10.4103/ijc.ijc_796_23","DOIUrl":"10.4103/ijc.ijc_796_23","url":null,"abstract":"<p><strong>Background: </strong>Radiation is an integral part of treatment of soft tissue sarcoma. Interstitial brachytherapy (ISBT) can deliver boost or radical dose sparing critical structures. Although this technology has been around the longest, it is seldom found in recent literature.</p><p><strong>Purpose: </strong>To report the outcomes of patients with soft tissue sarcoma who underwent ISBT after surgical resection.</p><p><strong>Materials and methods: </strong>We studied ISBT of extremity sarcoma in 60 patients aged between 3 and 77 years with a median age of 45 years and six patients belonging to the pediatric age group. Forty-two patients were males and 18 patients were females. Most common location was the thigh region (n = 27). The most common histological pattern was synovial sarcoma (n = 20), followed by extra-skeletal osteosarcoma [n = 10]. Utmost caution was taken to minimize the skin dose and the complications of ISBT. All patients underwent intraoperative brachytherapy catheter implantation. Brachytherapy consisted of high-dose rate (HDR) Iridium-192 interstitial implant with a range from 3 to 6 Gy per fraction with total dose ranging from 45 to 50 Gy. Fifty-five percent had combined external-beam radiation therapy (EBRT) and ISBT ranging between 4 and 10 sessions of ISBT. Maximum follow-up period was 72 months. The average depth of insertion of the implant was 5 mm below the skin. The patients were serially followed up and wound condition, skin toxicity, recurrence, and functional status of the limb were documented.</p><p><strong>Results: </strong>At final follow-up, there was 91% local control (55 patients) on the study population that received ISBT. All the surviving patients had functional limb. Three patients died due to chemotherapy-related neutropenic sepsis and disease progression. Most common complication encountered was skin problems. Fourteen patients had local irritation which gradually subsided; four patients had wound breakdown which was treated by debridement and secondary closure for two and by flap cover for other two patients. Overall survival rate was 86.4% with a median follow-up period of 33 months (2.75 years).</p><p><strong>Conclusions: </strong>Excellent local control and long-term survival with acceptable skin toxicities and wound complications were observed in our case series of patients treated with ISBT and ISBT + EBRT using an Iridium 192-based HDR system.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"535-540"},"PeriodicalIF":1.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel atypical signal pattern for MYC, BCL2 and BCL6 by fluorescent in situ hybridization in a case of triple hit lymphoma.","authors":"Anurita Pais, Rahul S Kulkarni, Rahul D Dhake, Firoz Ahmad, Rupa Dalvi, Sandhya Kandoor, Tanmay Wairkar, Kunal Sharma","doi":"10.4103/ijc.ijc_335_23","DOIUrl":"10.4103/ijc.ijc_335_23","url":null,"abstract":"<p><strong>Abstract: </strong>Triple hit lymphomas are uncommon subset of aggressive high-grade lymphomas that carry translocations involving MYC, BCL2, and BCL6 associated with aggressive behavior. Due to the rarity of these cases, documenting the atypical rare findings would lead to better characterization of these tumors. We present a case of Triple Hit diffuse large B-cell lymphoma (DLBCL) with an unusual atypical unbalanced rearrangements by fluorescent in situ hybridization (FISH) in all the MYC, BCL2, and BCL6 genes showing a MYC-IGH subtype indicating clonal evolution with complexity. This should be considered a warning sign towards a highly aggressive behavior that would aid in appropriate treatment selection. As the FISH patterns in TH remain under explored and our study reinforces the importance of characterizing the abnormal patterns for refinement of prognosis and treatment selection.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 4","pages":"560-564"},"PeriodicalIF":0.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147377434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monoclonal antibodies in 2025: From milestones to new frontiers.","authors":"Avinash Deo","doi":"10.4103/ijc.ijc_9_25","DOIUrl":"https://doi.org/10.4103/ijc.ijc_9_25","url":null,"abstract":"","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"329-331"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The usefulness of 3D CT reconstruction in surgical planning for glomus tympanicum.","authors":"Carlo Pane-Pianese, Roberto Corona-Cedillo, Nathaly Rivera-Sotelo, Ernesto Roldan-Valadez","doi":"10.4103/ijc.ijc_1344_21","DOIUrl":"https://doi.org/10.4103/ijc.ijc_1344_21","url":null,"abstract":"<p><strong>Abstract: </strong>Glomus tympanicum is a hypervascular, benign neoplasm with a slow rate of growth. The incidence of this pathology is higher in females than in males and mainly occurs in the fifth to sixth decade of life. Pulsatile tinnitus and hearing loss are the main clinical features. We present the case of a 70-year-old female patient who was admitted to the otolaryngology service with a 1-month history of epistaxis and equilibrium disorder that caused a ground-level fall.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"62 3","pages":"449-450"},"PeriodicalIF":1.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145573610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}